| Oncothyreon: Why I'm Buying Back In VFC submits: In March I announced that I had sold all of my position in Oncothyreon (ONTY) after information became public that Merck KGaA (MRK), ONTY's partner for the clinical development of Stimuvax, had halted all trials of the product after a patient had contracted encephalitis in one of the trials.Stimuvax is one of the new breed of cancer 'vaccines' being tested in multiple common forms of cancer, including breast and lung cancer.Complete Story » seekingalpha.com |
FDA Warns on Antibiotics in Livestock The FDA, worried about the rise of drug-resistant pathogens, stepped up its campaign to discourage the use of human antibiotics in farm animals. online.wsj.com |
Genoptix: Magic Formula Stock or Magic Value Trap? Gaurav Sharma submits:Looks like a good value stock.......now let's find out if its a trap.As of 07/30/2010 the stock has fallen 56% from its high.Cash = $140 M = 7.7$/shareMarket Cap = 300M = 17.19/shareFCF for 2009 = 30, 2008 = 22,2007 = 12.5Has had tremendous growth in the past.Does out of clinic blood evaluation and suggests treatments. Currently, oncologists are being squeezed. They are being paid the same amount even though costs are rising and hence they are looking to reduce expenses. Also, uninsured patients are increasing. Besides that competition is increasing as described below.Complete Story » seekingalpha.com |
Amyris Biotechnologies: Another Biofuel Company Seeks Public Funds, Let the Criticism Begin Greentech Media submits: by Michael KanellosAmyris amended the preliminary paperwork for an initial public offering yesterday. The company now says it hopes to sell 5.3 million shares of stock for $18 to $20 a share.Complete Story » seekingalpha.com |
Senior Veterans Reflect - Video Veterans Share Life Lessons Learned in Service feedproxy.google.com |